Cargando…
Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with many anticancer therapies and can negatively impact patients' quality of life and potentially limit the effectiveness of chemotherapy. Currently, CINV can be prevented in most patients with guideline-recom...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720881/ https://www.ncbi.nlm.nih.gov/pubmed/35570542 http://dx.doi.org/10.2174/1568009622666220513094352 |
_version_ | 1784843643818868736 |
---|---|
author | Aapro, Matti Jordan, Karin Scotté, Florian Celio, Luigi Karthaus, Meinolf Roeland, Eric |
author_facet | Aapro, Matti Jordan, Karin Scotté, Florian Celio, Luigi Karthaus, Meinolf Roeland, Eric |
author_sort | Aapro, Matti |
collection | PubMed |
description | Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with many anticancer therapies and can negatively impact patients' quality of life and potentially limit the effectiveness of chemotherapy. Currently, CINV can be prevented in most patients with guideline-recommended antiemetic regimens. However, clinicians do not always follow guidelines, and patients often face difficulties adhering to their prescribed treatments. Therefore, approaches to increase guideline adherence need to be implemented. NEPA is the first and only fixed combination antiemetic, composed of netupitant (oral)/fosnetupitant (intravenous) and palonosetron, which, together with dexamethasone, constitute a triple antiemetic combination recommended for the prevention of CINV for patients receiving highly emetogenic chemotherapy and for certain patients receiving moderately emetogenic chemotherapy. Thus, NEPA offers a convenient and straightforward antiemetic treatment that could improve adherence to guidelines. This review provides an overview of CINV, evaluates the accumulated evidence of NEPA's antiemetic activity and safety from clinical trials and real-world practice, and examines the preliminary evidence of antiemetic control with NEPA in daily clinical settings beyond those described in pivotal trials. Moreover, we review the utility of NEPA in controlling nausea and preserving patients’ quality of life during chemotherapy, two major concerns in managing patients with cancer. |
format | Online Article Text |
id | pubmed-9720881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-97208812022-12-19 Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice Aapro, Matti Jordan, Karin Scotté, Florian Celio, Luigi Karthaus, Meinolf Roeland, Eric Curr Cancer Drug Targets Oncology Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with many anticancer therapies and can negatively impact patients' quality of life and potentially limit the effectiveness of chemotherapy. Currently, CINV can be prevented in most patients with guideline-recommended antiemetic regimens. However, clinicians do not always follow guidelines, and patients often face difficulties adhering to their prescribed treatments. Therefore, approaches to increase guideline adherence need to be implemented. NEPA is the first and only fixed combination antiemetic, composed of netupitant (oral)/fosnetupitant (intravenous) and palonosetron, which, together with dexamethasone, constitute a triple antiemetic combination recommended for the prevention of CINV for patients receiving highly emetogenic chemotherapy and for certain patients receiving moderately emetogenic chemotherapy. Thus, NEPA offers a convenient and straightforward antiemetic treatment that could improve adherence to guidelines. This review provides an overview of CINV, evaluates the accumulated evidence of NEPA's antiemetic activity and safety from clinical trials and real-world practice, and examines the preliminary evidence of antiemetic control with NEPA in daily clinical settings beyond those described in pivotal trials. Moreover, we review the utility of NEPA in controlling nausea and preserving patients’ quality of life during chemotherapy, two major concerns in managing patients with cancer. Bentham Science Publishers 2022-09-20 2022-09-20 /pmc/articles/PMC9720881/ /pubmed/35570542 http://dx.doi.org/10.2174/1568009622666220513094352 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode |
spellingShingle | Oncology Aapro, Matti Jordan, Karin Scotté, Florian Celio, Luigi Karthaus, Meinolf Roeland, Eric Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice |
title | Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice |
title_full | Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice |
title_fullStr | Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice |
title_full_unstemmed | Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice |
title_short | Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice |
title_sort | netupitant-palonosetron (nepa) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720881/ https://www.ncbi.nlm.nih.gov/pubmed/35570542 http://dx.doi.org/10.2174/1568009622666220513094352 |
work_keys_str_mv | AT aapromatti netupitantpalonosetronnepaforpreventingchemotherapyinducednauseaandvomitingfromclinicaltrialstodailypractice AT jordankarin netupitantpalonosetronnepaforpreventingchemotherapyinducednauseaandvomitingfromclinicaltrialstodailypractice AT scotteflorian netupitantpalonosetronnepaforpreventingchemotherapyinducednauseaandvomitingfromclinicaltrialstodailypractice AT celioluigi netupitantpalonosetronnepaforpreventingchemotherapyinducednauseaandvomitingfromclinicaltrialstodailypractice AT karthausmeinolf netupitantpalonosetronnepaforpreventingchemotherapyinducednauseaandvomitingfromclinicaltrialstodailypractice AT roelanderic netupitantpalonosetronnepaforpreventingchemotherapyinducednauseaandvomitingfromclinicaltrialstodailypractice |